Production (Stage)
Evogene Ltd.
EVGN
$1.38
-$0.14-9.21%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 290.29% | 341.99% | 236.72% | 331.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 290.29% | 341.99% | 236.72% | 331.52% |
| Cost of Revenue | -- | 38.60% | 57.30% | 86.14% | 104.19% |
| Gross Profit | -- | 566.64% | 642.73% | 415.40% | 690.66% |
| SG&A Expenses | -- | -5.52% | -2.12% | -7.07% | -0.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 10.45% | 16.96% | 12.34% | -14.45% |
| Operating Income | -- | 16.03% | 9.36% | 1.61% | 28.85% |
| Income Before Tax | -- | 18.21% | 17.60% | 12.66% | 34.18% |
| Income Tax Expenses | -- | -130.77% | -72.09% | -136.67% | -58.97% |
| Earnings from Continuing Operations | -- | 18.33% | 17.68% | 13.03% | 34.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -60.17% | -56.34% | -35.28% | -30.17% |
| Net Income | -- | 13.00% | 12.84% | 10.36% | 34.62% |
| EBIT | -- | 16.03% | 9.36% | 1.61% | 28.85% |
| EBITDA | -- | 17.98% | 10.82% | 1.91% | 31.63% |
| EPS Basic | -- | 28.46% | 23.49% | 17.75% | 37.05% |
| Normalized Basic EPS | -- | 13.24% | 7.86% | 7.86% | 45.84% |
| EPS Diluted | -- | 28.46% | 23.49% | 17.75% | 37.05% |
| Normalized Diluted EPS | -- | 13.24% | 7.86% | 7.86% | 45.84% |
| Average Basic Shares Outstanding | -- | 21.54% | 16.25% | 10.80% | 5.17% |
| Average Diluted Shares Outstanding | -- | 21.54% | 16.25% | 10.80% | 5.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |